Evidence map›Paper›PMID 41579277›Full record

ArticleInternational ophthalmology2026

Preserflo microshunt in a real-life UK tertiary setting: success rates, safety profile, and postoperative management.

Giovanni Fossati, Marco Trevisi, Modupe Sodeinde, Luca Pagano, Mario R Romano, Lina Osman, Usman Sarodia, Huzaifa Malick

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giovanni FossatiOphthalmology Department, University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, LE1 5WW, UK.
Marco TrevisiEye Center, Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, Italy. Marco.Trevisi@royalberkshire.nhs.uk.
Modupe SodeindeOphthalmology Department, University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, LE1 5WW, UK.
Luca PaganoEye Center, Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, Italy.
Mario R RomanoDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Lina OsmanOphthalmology Department, University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, LE1 5WW, UK.
Usman SarodiaOphthalmology Department, University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, LE1 5WW, UK.
Huzaifa MalickOphthalmology Department, University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, LE1 5WW, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the efficacy and safety of PreserFlo MicroShunt in a UK tertiary glaucoma centre at one year follow-up.

methodsthis is a retrospective, single-centre study of eyes with glaucoma that underwent PreserFlo MicroShunt implantation. Success was defined as IOP between 6 and 21 mmHg (range 6-17 and 6-14 mmHg was also evaluated) and a reduction of at least 20% of preoperative IOP; success was defined as complete (CS) if without hypotensive medications, and as overall (OS), if with or without medications. Secondary outcomes included final IOP, final number of glaucoma drops, final BCVA.

resultsa total of 69 eyes were included in the study. The CS and OS for IOP 6-21 mmHg were achieved in 73.9% and 79.7%, respectively. For the range of IOP 6-17 mmHg, 72.5% and 78.3%, and for the range of IOP 6-14 mmHg, 55.1% and 58.0%. The mean IOP was significantly reduced from 24.7 ± 7.2 mmHg at baseline to 12.4 ± 5.0 mmHg (p < 0.0001). The most frequent adverse event was transient early hypotony (28.9%), followed by hyphaema (11.5%) and choroidal effusion (8.6%). Aqueous misdirection occurred in two pseudophakic eyes with primary angle-closure glaucoma (PACG), representing a rare but vision-threatening complication in this setting.

conclusionPreserFlo MicroShunt was effective and safe in the follow-up period and achieved IOP results in the low teens.

Indexed as

GlaucomaGlaucoma Drainage ImplantsIntraocular PressurePostoperative CareVisual AcuityFemaleFollow-Up StudiesHumansMaleRetrospective StudiesTertiary Care CentersTreatment OutcomeUnited KingdomGlaucomaPreserFloSafety profilesSuccess rates

Identifiers

PMID41579277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.